Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers
12/08/2026 13:05
BRIEF-Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers Aug 12 (Reuters) - Natera, Inc. NTRA.O:
NATERA TO SUPPORT NEW CLINICAL TRIAL ASSESSING CTDNA DYNAMICS WITH LATITUDE™ IN ADVANCED SKIN CANCERS
NATERA, - TRIAL TO ASSESS CTDNA DYNAMICS IN ADVANCED SKIN CANCER PATIENTS USING LATITUDE MRD TESTING
Source text: ID:nBw5V3G7ra
Further company coverage: NTRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers